Dr. Daniel P. Friedmann, M.D.
Dermatology (Procedural Dermatology Physician)
At a glance
- In the NPI registry since
- 2008
Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Procedural Dermatology Physician primary
TX license P8471 (first issued 2013; active) -
Dermatology Physician
TX license P8471 (first issued 2013; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 35 payments worth $10,318 in total to this clinician.
| AbbVie Inc. | $8,359 |
|---|---|
| Lumenis Be LTD | $1,800 |
| Galderma Laboratories, L.P. | $66.52 |
| Revance Therapeutics, Inc. | $50.46 |
| Boston Scientific Corporation | $27.26 |
| Incyte Corporation | $15.41 |
| Consulting Fee | $6,800 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,800 |
| Food and Beverage | $1,101 |
| Travel and Lodging | $617 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Sep 18, 2025 | Consulting Fee | $6,800 |
| Lumenis Be LTD Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) M22 · Dermathology | $1,800 |
| AbbVie Inc. Sep 6, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $248 |
| AbbVie Inc. Sep 5, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $215 |
| AbbVie Inc. Sep 5, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $129 |
| AbbVie Inc. Sep 6, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $25.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $258,815 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants
AbbVie Inc. · Completed · NCT06399718 - A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
AbbVie Inc. · Recruiting · NCT06734351 - M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
AbbVie Inc. - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - M21-841 - M21-841 NOA Volume - Mid Face US Pivotal Study
AbbVie Inc. - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.